Michael Girardi, MD
Year elected: 2008
Current membership category: Active
Professor of Dermatology; Director-Residency ProgramYale School of Medicine
Dept. of Dermatology
333 Cedar Street
P.O. Box 208059
New Haven, CT 06520-8059
United States of America
Dr. Michael Girardi is a Professor in Dermatology at Yale with academic interests in tumor immunology. His laboratory primarily focuses on the immunoregulation of cancer, studying how local immune cells both antagonize and promote the emergence of carcinoma. Dr. Girardi’s laboratory studies the effects of chronic inflammation on epithelial transformation and has recently helped elucidate: (1) a novel tumor-promoting T cell subset that supports an inflammatory state and substantially enhances cutaneous carcinogenesis; (2) an almost absolute requirement for skin-resident dendritic cells for induction of chemical carcinogenesis; (3) an intraepithelial gamma/delta T cell population that locally inhibits tumor development, revealing that these tissue-resident T cells are key to host tumor immunosurveillance; and (4) the major role of NKG2D-ligands as stress molecules that trigger the dynamic intraepithelial reorganization of T cells, dendritic cells, and NKT cells in skin and within early tumors. The findings have major implications for the identification of novel immune targets of cancer prevention and therapy for a spectrum of malignancies. In addition, Dr. Girardi’s clinical expertise is primarily in the treatment of cutaneous lymphoma and graft-versus-host disease, including novel approaches to the extracorporeal production of monocyte-derived dendritic cells. He recently demonstrated the safety and utility of a novel methodology for the large-scale generation of dendritic antigen presenting cells for cancer immunotherapy in clinical trial for cutaneous lymphoma.
Yale School of Medicine (Primary)
Harriet Margot Kluger, MD is the representative at this institution.